Advertisement

Digestive Diseases and Sciences

, Volume 64, Issue 1, pp 285–286 | Cite as

Correction to: Hepatitis B Surface Antigen Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a: Week 120 Analysis

  • Sang Hoon Ahn
  • Patrick MarcellinEmail author
  • Xiaoli Ma
  • Florin A. Caruntu
  • Won Young Tak
  • Magdy Elkhashab
  • Wan-Long Chuang
  • Fehmi Tabak
  • Rajiv Mehta
  • Jörg Petersen
  • William Guyer
  • Belinda Jump
  • Alain Chan
  • Mani Subramanian
  • Gerald Crans
  • Scott Fung
  • Maria Buti
  • Giovanni B. Gaeta
  • Aric J. Hui
  • George Papatheodoridis
  • Robert Flisiak
  • Henry L. Y. ChanEmail author
Correction
  • 146 Downloads

Correction to: Digestive Diseases and Sciences  https://doi.org/10.1007/s10620-018-5251-9

The original version of this article unfortunately contained affiliation and textual errors. This has been corrected with this erratum.

Affiliation of eleventh author was incorrectly assigned. Dr. William Guyer is affiliated with Gilead Sciences Inc, Foster City, CA, USA.

In Results section, Safety Profile subsection, the sentence, ‘Rates of serious adverse events were 11%, 10%, 7%, and 10% in groups A, B, C, and D, respectively, and 6%, 3%, and 5% in groups A, B, and D, respectively, among those patients who were treated with TDF’ should read as below:

Rates of serious adverse events were 11%, 10%, 7%, and 10% in groups A, B, C, and D, respectively, and 6%, 3%, and 5% in groups A, B, and D, respectively, among those patients who were retreated with TDF.

In Table 2, header ‘Mean HBV DNA change from baseline, log10 IU/mL (SD)’ row 3 is missing ‘B’ in genotype. Revised version of the Table 2 is given below.
Table 2

Efficacy results at week 120 by baseline HBeAg status and genotype

Response

Group A (n = 186)

TDF + PEG-IFN

for 48 weeks

Group B (n = 184)

TDF + PEG-IFN

for 16 weeks, TDF for 32 weeks

Group C (n = 185)

TDF for 120 weeks

Group D (n = 185)

PEG-IFN

for 48 weeks

HBsAg loss, Kaplan–Meier estimate (%)

 Overall

10.36

3.49

0

3.51

 HBeAg positive

9.73

5.15

0

5.23

 HBeAg negative

10.99

1.32

0

1.28

HBsAg seroconversion, Kaplan–Meier estimate (%)

 Overall

10.08

0.56

0

2.87

 HBeAg positive

10.41

0.97

0

4.10

 HBeAg negative

9.65

0

0

1.28

Mean HBsAg change from baseline, log10 IU/mL (SD)

 Overall

− 2.4 (2.4)

− 0.8 (1.5)

− 0.4 (0.7)

− 1.1 (1.6)

 Genotype A

− 4.2 (2.3)

− 0.7 (1.2)

0.0 (0.6)

 Genotype B

− 2.2 (2.1)

− 1.0 (1.0)

− 0.7 (0.6)

− 1.2 (1.2)

 Genotype C

− 1.5 (2.2)

− 0.4 (1.5)

− 0.4 (0.7)

− 1.1 (1.7)

 Genotype D

− 2.0 (2.3)

− 1.6 (2.6)

− 0.2 (0.4)

− 1.5 (2.9)

 HBeAg positive

− 2.2 (2.6)

− 1.2 (1.9)

− 0.7 (0.7)

− 1.3 (2.1)

 HBeAg negative

− 2.5 (2.1)

− 0.4 (0.9)

− 0.1 (0.4)

− 1.0 (1.1)

Mean HBV DNA change from baseline, log10 IU/mL (SD)

 Overall

− 4.2 (2.1)

− 4.3 (2.0)

− 5.7 (1.6)

− 3.5 (2.0)

 Genotype A

− 4.0 (1.9)

− 5.1 (2.1)

− 1.9 (2.0)

 Genotype B

− 4.7 (2.0)

− 4.2 (2.5)

− 5.8 (1.4)

− 3.3 (1.8)

 Genotype C

− 4.2 (2.9)

− 4.4 (1.5)

− 5.9 (1.6)

− 3.4 (2.3)

 Genotype D

− 4.0 (1.8)

− 4.1 (3.0)

− 5.3 (1.7)

− 5.1 (1.9)

 HBeAg positive

− 5.5 (1.6)

− 5.3 (1.5)

− 6.6 (1.2)

− 4.9 (1.6)

 HBeAg negative

− 2.9 (1.7)

− 3.4 (1.9)

− 4.5 (1.3)

− 2.5 (1.8)

Copyright information

© The Author(s) 2018

Authors and Affiliations

  • Sang Hoon Ahn
    • 1
  • Patrick Marcellin
    • 2
    Email author
  • Xiaoli Ma
    • 3
  • Florin A. Caruntu
    • 4
  • Won Young Tak
    • 5
  • Magdy Elkhashab
    • 6
  • Wan-Long Chuang
    • 7
  • Fehmi Tabak
    • 8
  • Rajiv Mehta
    • 9
  • Jörg Petersen
    • 10
  • William Guyer
    • 11
  • Belinda Jump
    • 11
  • Alain Chan
    • 11
  • Mani Subramanian
    • 11
  • Gerald Crans
    • 11
  • Scott Fung
    • 12
  • Maria Buti
    • 13
  • Giovanni B. Gaeta
    • 14
  • Aric J. Hui
    • 15
    • 16
  • George Papatheodoridis
    • 17
  • Robert Flisiak
    • 18
  • Henry L. Y. Chan
    • 19
    Email author
  1. 1.Department of Internal Medicine, Yonsei University College of MedicineBrain Korea 21 Plus Project for Medical ScienceSeoulRepublic of Korea
  2. 2.Hôpital BeaujonUniversity Paris-DiderotClichyFrance
  3. 3.Drexel University College of MedicinePhiladelphiaUSA
  4. 4.National Institute for Infectious Diseases “Matei Bals”BucharestRomania
  5. 5.Kyungpook National University HospitalDaeguSouth Korea
  6. 6.Toronto Liver CentreTorontoCanada
  7. 7.Kaohsiung Medical University HospitalKaohsiung Medical UniversityKaohsiungTaiwan
  8. 8.Cerrahpasa Medical FacultyUniversity of IstanbulIstanbulTurkey
  9. 9.Liver ClinicSuratIndia
  10. 10.IFI Institute for Interdisciplinary Medicine, Asklepios Klinik St. GeorgeUniversity of HamburgHamburgGermany
  11. 11.Gilead Sciences IncFoster CityUSA
  12. 12.Toronto General HospitalTorontoCanada
  13. 13.Hepatology UnitHospital Universitari Vall d’Hebron and CIBEREHD del Instituto Carlos IIIBarcelonaSpain
  14. 14.Infectious Diseases and Viral Hepatitis UnitUniversity of Campania “Luigi Vanvitelli”NaplesItaly
  15. 15.The Chinese University of Hong KongHong KongChina
  16. 16.Alice Ho Miu Ling Nethersole HospitalHong KongChina
  17. 17.Medical School of National and Kapodistrian University of AthensGeneral Hospital of Athens “Laiko”AthensGreece
  18. 18.Department of Infectious Diseases and HepatologyMedical University of BialystokBiałystokPoland
  19. 19.Department of Medicine and Therapeutics and Institute of Digestive DiseaseThe Chinese University of Hong KongHong KongChina

Personalised recommendations